Page results
-
Read more about the Halcyon linear accelerator, aimed at making cancer treatment faster, more comfortable, and more precise for patients.
-
Dr Katherine Clesham is a consultant haematologist specialising in the treatment of teenagers and young adults with acute leukaemia and patients undergoing stem cell transplantation and CAR-T therapy.
-
Patients with COVID-19 will be given the cystic fibrosis drug ‘Dornase alfa’ to determine if it can help improve survival by reducing excess inflammation in the lungs in a trial at UCLH.
-
A drug commonly used to treat cystic fibrosis improved outcomes for patients with severe COVID-19 pneumonia and could be used to treat other respiratory infections, according to clinical trial results from researchers at UCLH, UCL and the Francis Crick Institute.
-
This page tells you about having a Non-Tunnelled CVC Line Insertion (Vascath). This page is for those patients who have been referred to Interventional Radiology.
-
Neurological complications of COVID-19 can include delirium, brain inflammation, stroke and nerve damage, finds a new UCL and UCLH-led study.
-
This patient information is intended to help patients suffering from long COVID to better manage and understand their fatigue.
-
UCLH will be part of a major UK research study looking at the long-term health impacts of COVID-19.
-
We’re delighted to announce that our Grafton Way Elective Surgical Hub has been successfully accredited as an elective surgical hub delivering high standards in clinical and operational practice.
-
The iconic run has returned to its regular time of the year, following two years’ disruption following the pandemic and will take place on Sunday 2 October 2022. We are lucky enough to have five people running for UCLH Charity. The money they raise will help us support patients, staff and research at UCLH.
File results
-
FOI/2024/0148 - Cleaning audit system at Trust
-
FOI/2024/0149 - National Hospital for Neurology and Neurosurgery (NHNN) admissions 2018-2023
-
FOI/2024/0155 - Immunotherapy treatments for lung cancer
-
FOI/2024/0162 - Various technology systems/ services used at Trust
-
FOI/2024/0163 - Renal cell carcinoma and melanoma treatments
-
FOI/2024/0166 - Recruitment systems/CRM platform
-
FOI/2024/0171 - Dermatology consultants
-
FOI/2024/0172 - Patients excluded from care at the Trust 2010-2023
-
FOI/2024/0179 - Water usage/ procurement
-
FOI/2024/0183 - Immunology Hidradenitis Suppurativa (HS) treatment